Use the keywords feature with a free QxMD account.
Use Read by QxMD to access full text via your institution or open access sources.
Read also provides personalized recommendations to keep you up to date in your field.
Existing User
Sign InNew to Read
Sign Up#1
JOURNAL ARTICLE
E Tabouret, J Furtner, T Graillon, A Silvani, E Le Rhun, R Soffietti, G Lombardi, J M Sepúlveda-Sánchez, P Brandal, M Bendszus, V Golfinopoulos, T Gorlia, M Weller, F Sahm, W Wick, M Preusser
BACKGROUND: We previously reported that tumor 3D volume growth rate (3DVGR) classification could help in the assessment of drug activity in patients with meningioma using three main classes and a total of five subclasses: class 1: decrease; 2: stabilization or severe slowdown; 3: progression. The EORTC-BTG-1320 clinical trial was a randomized phase II trial evaluating the efficacy of trabectedin for recurrent WHO 2 or 3 meningioma. Our objective was to evaluate the discriminative value of 3DVGR classification in the EORTC-BTG-1320...
March 7, 2024: Neuro-oncology
#2
RANDOMIZED CONTROLLED TRIAL
Ingo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, Mehdi Touat, Katherine B Peters, Jennifer Clarke, Joe Mendez, Shlomit Yust-Katz, Liam Welsh, Warren P Mason, François Ducray, Yoshie Umemura, Burt Nabors, Matthias Holdhoff, Andreas F Hottinger, Yoshiki Arakawa, Juan M Sepulveda, Wolfgang Wick, Riccardo Soffietti, James R Perry, Pierre Giglio, Macarena de la Fuente, Elizabeth A Maher, Steven Schoenfeld, Dan Zhao, Shuchi S Pandya, Lori Steelman, Islam Hassan, Patrick Y Wen, Timothy F Cloughesy
BACKGROUND: Isocitrate dehydrogenase (IDH)-mutant grade 2 gliomas are malignant brain tumors that cause considerable disability and premature death. Vorasidenib, an oral brain-penetrant inhibitor of mutant IDH1 and IDH2 enzymes, showed preliminary activity in IDH-mutant gliomas. METHODS: In a double-blind, phase 3 trial, we randomly assigned patients with residual or recurrent grade 2 IDH-mutant glioma who had undergone no previous treatment other than surgery to receive either oral vorasidenib (40 mg once daily) or matched placebo in 28-day cycles...
August 17, 2023: New England Journal of Medicine
#3
REVIEW
A Pellerino, D Garbossa, R Rudà, R Soffietti
Traditionally, in the past, most of central nervous system metastases from solid tumors were associated with an advanced phase of the disease needing palliation only, while to date they increasingly develop as an early and/or solitary relapse in patients with the systemic disease under control. This review will cover all the aspects of a modern management of brain and leptomeningeal metastases from diagnosis to the different therapeutic options, either local (surgery, stereotactic radiosurgery, whole-brain radiotherapy with hippocampal avoidance) or systemic...
March 27, 2023: Revue Neurologique
#4
JOURNAL ARTICLE
Abigirl Machingura, Mekdes Taye, Jammbe Musoro, Jolie Ringash, Madeline Pe, Corneel Coens, Francesca Martinelli, Dongsheng Tu, Ethan Basch, Yvonne Brandberg, Mogens Grønvold, Alexander Eggermont, Fatima Cardoso, Jan Van Meerbeeck, Winette T A van der Graaf, Martin Taphoorn, Jaap C Reijneveld, Riccardo Soffietti, Jeff Sloan, Galina Velikova, Henning Flechtner, Andrew Bottomley
INTRODUCTION: The European Organisation for Research and Treatment of Cancer Quality of Life Core Questionnaire (EORTC QLQ-C30) measures 15 health-related quality of life (HRQoL) scales relevant to the disease and treatment of patients with cancer. A study by Martinelli (2011) demonstrated that these scales could be grouped into three main clusters: physical, psychological and gastrointestinal. This study aims to validate Martinelli's findings in an independent dataset and evaluate whether these clusters are consistent across cancer types and patient characteristics...
July 2022: European Journal of Cancer
#5
JOURNAL ARTICLE
Riccardo Soffietti, Chetan Bettegowda, Ingo K Mellinghoff, Katherine E Warren, Manmeet S Ahluwalia, John F De Groot, Evanthia Galanis, Mark R Gilbert, Kurt A Jaeckle, Emilie Le Rhun, Roberta Rudà, Joan Seoane, Niklas Thon, Yoshie Umemura, Michael Weller, Martin J van den Bent, Michael A Vogelbaum, Susan M Chang, Patrick Y Wen
BACKGROUND: There is an extensive literature highlighting the utility of blood-based liquid biopsies in several extracranial tumors for diagnosis and monitoring. METHODS: The RANO (Response Assessment in Neuro-Oncology) group developed a multidisciplinary international Task Force to review the English literature on liquid biopsy in gliomas focusing on the most frequently used techniques, that is circulating tumor DNA, circulating tumor cells, and extracellular vesicles in blood and CSF...
June 1, 2022: Neuro-oncology
#6
REVIEW
T J von Oertzen, A Macerollo, M A Leone, E Beghi, M Crean, S Oztuk, C Bassetti, A Twardzik, D Bereczki, G Di Liberto, R Helbok, C Oreja-Guevara, A Pisani, A Sauerbier, J Sellner, R Soffietti, M Zedde, E Bianchi, B Bodini, F Cavallieri, L Campiglio, L F Maia, A Priori, M Rakusa, P Taba, E Moro, T M Jenkins
BACKGROUND AND PURPOSE: The recent SARS-CoV-2 pandemic has posed multiple challenges to the practice of clinical neurology including recognition of emerging neurological complications and management of coexistent neurological diseases. In a fast-evolving pandemic, evidence-based studies are lacking in many areas. This paper presents European Academy of Neurology (EAN) expert consensus statements to guide neurologists caring for patients with COVID-19. METHODS: A refined Delphi methodology was applied...
January 2021: European Journal of Neurology
#7
JOURNAL ARTICLE
E Moro, A Priori, E Beghi, R Helbok, L Campiglio, C L Bassetti, E Bianchi, L F Maia, S Ozturk, F Cavallieri, M Zedde, J Sellner, D Bereczki, M Rakusa, G Di Liberto, A Sauerbier, A Pisani, A Macerollo, R Soffietti, P Taba, M Crean, A Twardzik, C Oreja-Guevara, B Bodini, T M Jenkins, T J von Oertzen
BACKGROUND AND PURPOSE: Although the main clinical features of COVID-19 infection are pulmonary, several associated neurological signs, symptoms and diseases are emerging. The incidence and characteristics of neurological complications are unclear. For this reason, the European Academy of Neurology (EAN) core COVID-19 Task Force initiated a survey on neurological symptoms observed in patients with COVID-19 infection. METHODS: A 17-question online survey was made available on the EAN website and distributed to EAN members and other worldwide physicians starting on 9 April 2020...
September 2020: European Journal of Neurology
#8
REVIEW
Achal Singh Achrol, Robert C Rennert, Carey Anders, Riccardo Soffietti, Manmeet S Ahluwalia, Lakshmi Nayak, Solange Peters, Nils D Arvold, Griffith R Harsh, Patricia S Steeg, Steven D Chang
An estimated 20% of all patients with cancer will develop brain metastases, with the majority of brain metastases occurring in those with lung, breast and colorectal cancers, melanoma or renal cell carcinoma. Brain metastases are thought to occur via seeding of circulating tumour cells into the brain microvasculature; within this unique microenvironment, tumour growth is promoted and the penetration of systemic medical therapies is limited. Development of brain metastases remains a substantial contributor to overall cancer mortality in patients with advanced-stage cancer because prognosis remains poor despite multimodal treatments and advances in systemic therapies, which include a combination of surgery, radiotherapy, chemotherapy, immunotherapy and targeted therapies...
January 17, 2019: Nature Reviews. Disease Primers
#9
REVIEW
C Chiavazza, A Pellerino, F Ferrio, A Cistaro, R Soffietti, R Rudà
Primary Central Nervous System Lymphoma (PCNSL) is a rare neoplasm that can involve brain, eye, leptomeninges, and rarely spinal cord. PCNSL lesions most typically enhance homogeneously on T1-weighted magnetic resonance imaging (MRI) and appear T2-hypointense, but high variability in MRI features is commonly encountered. Neurological symptoms and MRI findings may mimic high grade gliomas (HGGs), tumefactive demyelinating lesions (TDLs), or infectious and granulomatous diseases. Advanced MRI techniques (MR diffusion, spectroscopy, and perfusion) and metabolic imaging, such as Fluorodeoxyglucose Positron Emission Tomography (FDG-PET) or amino acid PET (usually employing methionine), may be useful in distinguishing these different entities and monitoring the disease course...
2018: BioMed Research International
#10
REVIEW
Brian M Alexander, Paul D Brown, Manmeet S Ahluwalia, Hidefumi Aoyama, Brigitta G Baumert, Susan M Chang, Laurie E Gaspar, Steven N Kalkanis, David R Macdonald, Minesh P Mehta, Riccardo Soffietti, John H Suh, Martin J van den Bent, Michael A Vogelbaum, Jeffrey S Wefel, Eudocia Q Lee, Patrick Y Wen
The goals of therapeutic and biomarker development form the foundation of clinical trial design, and change considerably from early-phase to late-phase trials. From these goals, decisions on specific clinical trial design elements, such as endpoint selection and statistical approaches, are formed. Whereas early-phase trials might focus on finding a therapeutic signal to make decisions on further development, late-phase trials focus on the confirmation of therapeutic impact by considering clinically meaningful endpoints...
January 2018: Lancet Oncology
#11
REVIEW
D Ross Camidge, Eudocia Q Lee, Nancy U Lin, Kim Margolin, Manmeet S Ahluwalia, Martin Bendszus, Susan M Chang, Janet Dancey, Elisabeth G E de Vries, Gordon J Harris, F Stephen Hodi, Andrew B Lassman, David R Macdonald, David M Peereboom, David Schiff, Ricardo Soffietti, Martin J van den Bent, Jeffrey S Wefel, Patrick Y Wen
Patients with active CNS disease are often excluded from clinical trials, and data regarding the CNS efficacy of systemic agents are usually obtained late in the drug development process or not at all. In this guideline from the Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group, we provide detailed recommendations on when patients with brain metastases from solid tumours should be included or excluded in clinical trials of systemic agents. We also discuss the limitations of retrospective studies in determining the CNS efficacy of systemic drugs...
January 2018: Lancet Oncology
#12
RANDOMIZED CONTROLLED TRIAL
T M Churilla, E Handorf, S Collette, L Collette, Y Dong, A A Aizer, M Kocher, R Soffietti, B M Alexander, S E Weiss
BACKGROUND: The absence of a survival benefit for whole brain radiotherapy (WBRT) among randomized trials has been attributed to a competing risk of death from extracranial disease. We re-analyzed EORTC 22952 to assess the impact of WBRT on survival for patients with controlled extracranial disease or favorable prognoses. PATIENTS AND METHODS: We utilized Cox regression, landmark analysis, and the Kaplan-Meier method to evaluate the impact of WBRT on survival accounting for (i) extracranial progression as a time-dependent covariate in all patients and (ii) diagnosis-specific graded prognostic assessment (GPA) score in patients with primary non-small-cell lung cancer (NSCLC)...
October 1, 2017: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#13
REVIEW
Lakshmi Nayak, Lisa M DeAngelis, Alba A Brandes, David M Peereboom, Evanthia Galanis, Nancy U Lin, Riccardo Soffietti, David R Macdonald, Marc Chamberlain, James Perry, Kurt Jaeckle, Minesh Mehta, Roger Stupp, Alona Muzikansky, Elena Pentsova, Timothy Cloughesy, Fabio M Iwamoto, Joerg-Christian Tonn, Michael A Vogelbaum, Patrick Y Wen, Martin J van den Bent, David A Reardon
BACKGROUND: The Macdonald criteria and the Response Assessment in Neuro-Oncology (RANO) criteria define radiologic parameters to classify therapeutic outcome among patients with malignant glioma and specify that clinical status must be incorporated and prioritized for overall assessment. But neither provides specific parameters to do so. We hypothesized that a standardized metric to measure neurologic function will permit more effective overall response assessment in neuro-oncology. METHODS: An international group of physicians including neurologists, medical oncologists, radiation oncologists, and neurosurgeons with expertise in neuro-oncology drafted the Neurologic Assessment in Neuro-Oncology (NANO) scale as an objective and quantifiable metric of neurologic function evaluable during a routine office examination...
May 1, 2017: Neuro-oncology
#14
T M Churilla, E Handorf, R Soffietti, M Kocher, A A Aizer, L Collette, S Collette, Y Dong, B M Alexander, S E Weiss
No abstract text is available yet for this article.
October 1, 2016: International Journal of Radiation Oncology, Biology, Physics
#15
JOURNAL ARTICLE
Vijay Ramaswamy, Thomas Hielscher, Stephen C Mack, Alvaro Lassaletta, Tong Lin, Kristian W Pajtler, David T W Jones, Betty Luu, Florence M G Cavalli, Kenneth Aldape, Marc Remke, Martin Mynarek, Stefan Rutkowski, Sridharan Gururangan, Roger E McLendon, Eric S Lipp, Christopher Dunham, Juliette Hukin, David D Eisenstat, Dorcas Fulton, Frank K H van Landeghem, Mariarita Santi, Marie-Lise C van Veelen, Erwin G Van Meir, Satoru Osuka, Xing Fan, Karin M Muraszko, Daniela P C Tirapelli, Sueli M Oba-Shinjo, Suely K N Marie, Carlos G Carlotti, Ji Yeoun Lee, Amulya A Nageswara Rao, Caterina Giannini, Claudia C Faria, Sofia Nunes, Jaume Mora, Ronald L Hamilton, Peter Hauser, Nada Jabado, Kevin Petrecca, Shin Jung, Luca Massimi, Massimo Zollo, Giuseppe Cinalli, László Bognár, Almos Klekner, Tibor Hortobágyi, Sarah Leary, Ralph P Ermoian, James M Olson, Jeffrey R Leonard, Corrine Gardner, Wieslawa A Grajkowska, Lola B Chambless, Jason Cain, Charles G Eberhart, Sama Ahsan, Maura Massimino, Felice Giangaspero, Francesca R Buttarelli, Roger J Packer, Lyndsey Emery, William H Yong, Horacio Soto, Linda M Liau, Richard Everson, Andrew Grossbach, Tarek Shalaby, Michael Grotzer, Matthias A Karajannis, David Zagzag, Helen Wheeler, Katja von Hoff, Marta M Alonso, Teresa Tuñon, Ulrich Schüller, Karel Zitterbart, Jaroslav Sterba, Jennifer A Chan, Miguel Guzman, Samer K Elbabaa, Howard Colman, Girish Dhall, Paul G Fisher, Maryam Fouladi, Amar Gajjar, Stewart Goldman, Eugene Hwang, Marcel Kool, Harshad Ladha, Elizabeth Vera-Bolanos, Khalida Wani, Frank Lieberman, Tom Mikkelsen, Antonio M Omuro, Ian F Pollack, Michael Prados, H Ian Robins, Riccardo Soffietti, Jing Wu, Phillipe Metellus, Uri Tabori, Ute Bartels, Eric Bouffet, Cynthia E Hawkins, James T Rutka, Peter Dirks, Stefan M Pfister, Thomas E Merchant, Mark R Gilbert, Terri S Armstrong, Andrey Korshunov, David W Ellison, Michael D Taylor
PURPOSE: Posterior fossa ependymoma comprises two distinct molecular variants termed EPN_PFA and EPN_PFB that have a distinct biology and natural history. The therapeutic value of cytoreductive surgery and radiation therapy for posterior fossa ependymoma after accounting for molecular subgroup is not known. METHODS: Four independent nonoverlapping retrospective cohorts of posterior fossa ependymomas (n = 820) were profiled using genome-wide methylation arrays. Risk stratification models were designed based on known clinical and newly described molecular biomarkers identified by multivariable Cox proportional hazards analyses...
July 20, 2016: Journal of Clinical Oncology
#16
JOURNAL ARTICLE
Antonella Castellano, Marina Donativi, Roberta Rudà, Giorgio De Nunzio, Marco Riva, Antonella Iadanza, Luca Bertero, Matteo Rucco, Lorenzo Bello, Riccardo Soffietti, Andrea Falini
OBJECTIVES: To explore the role of diffusion tensor imaging (DTI)-based histogram analysis and functional diffusion maps (fDMs) in evaluating structural changes of low-grade gliomas (LGGs) receiving temozolomide (TMZ) chemotherapy. METHODS: Twenty-one LGG patients underwent 3T-MR examinations before and after three and six cycles of dose-dense TMZ, including 3D-fluid-attenuated inversion recovery (FLAIR) sequences and DTI (b = 1000 s/mm(2), 32 directions). Mean diffusivity (MD), fractional anisotropy (FA), and tensor-decomposition DTI maps (p and q) were obtained...
May 2016: European Radiology
#17
JOURNAL ARTICLE
L Barault, A Amatu, F E Bleeker, C Moutinho, C Falcomatà, V Fiano, A Cassingena, G Siravegna, M Milione, P Cassoni, F De Braud, R Rudà, R Soffietti, T Venesio, A Bardelli, P Wesseling, P de Witt Hamer, F Pietrantonio, S Siena, M Esteller, A Sartore-Bianchi, F Di Nicolantonio
BACKGROUND: O(6)-methyl-guanine-methyl-transferase (MGMT) silencing by promoter methylation may identify cancer patients responding to the alkylating agents dacarbazine or temozolomide. PATIENTS AND METHODS: We evaluated the prognostic and predictive value of MGMT methylation testing both in tumor and cell-free circulating DNA (cfDNA) from plasma samples using an ultra-sensitive two-step digital PCR technique (methyl-BEAMing). Results were compared with two established techniques, methylation-specific PCR (MSP) and Bs-pyrosequencing...
September 2015: Annals of Oncology: Official Journal of the European Society for Medical Oncology
#18
REVIEW
Nancy U Lin, Eudocia Q Lee, Hidefumi Aoyama, Igor J Barani, Daniel P Barboriak, Brigitta G Baumert, Martin Bendszus, Paul D Brown, D Ross Camidge, Susan M Chang, Janet Dancey, Elisabeth G E de Vries, Laurie E Gaspar, Gordon J Harris, F Stephen Hodi, Steven N Kalkanis, Mark E Linskey, David R Macdonald, Kim Margolin, Minesh P Mehta, David Schiff, Riccardo Soffietti, John H Suh, Martin J van den Bent, Michael A Vogelbaum, Patrick Y Wen
CNS metastases are the most common cause of malignant brain tumours in adults. Historically, patients with brain metastases have been excluded from most clinical trials, but their inclusion is now becoming more common. The medical literature is difficult to interpret because of substantial variation in the response and progression criteria used across clinical trials. The Response Assessment in Neuro-Oncology Brain Metastases (RANO-BM) working group is an international, multidisciplinary effort to develop standard response and progression criteria for use in clinical trials of treatment for brain metastases...
June 2015: Lancet Oncology
#19
MULTICENTER STUDY
Elizabeth Vera-Bolanos, Kenneth Aldape, Ying Yuan, Jimin Wu, Khalida Wani, Mary Jo Necesito-Reyes, Howard Colman, Girish Dhall, Frank S Lieberman, Philippe Metellus, Tom Mikkelsen, Antonio Omuro, Sonia Partap, Michael Prados, H Ian Robins, Riccardo Soffietti, Jing Wu, Mark R Gilbert, Terri S Armstrong
BACKGROUND: Ependymomas are rare CNS tumors. Previous studies describing the clinical course of ependymoma patients were restricted to small sample sizes, often with patients at a specific institution. METHODS: Clinically annotated ependymoma tissue samples from 19 institutions were centrally reviewed. Patients were all adults aged 18 years or older at the time of diagnosis. Potential prognostic clinical factors identified on univariate analysis were included in a multivariate Cox proportional hazards model with backwards selection to model progression-free survival...
March 2015: Neuro-oncology
#20
REVIEW
Jason T Huse, Max Wallace, Kenneth D Aldape, Mitchel S Berger, Chetan Bettegowda, Daniel J Brat, Daniel P Cahill, Timothy Cloughesy, Daphne A Haas-Kogan, Marco Marra, C Ryan Miller, Sarah J Nelson, Sofie R Salama, Riccardo Soffietti, Patrick Y Wen, Stephen Yip, Katharine Yen, Joseph F Costello, Susan Chang
Diffuse gliomas consist of both low- and high-grade varieties, each with distinct morphological and biological features. The often extended periods of relative indolence exhibited by low-grade gliomas (LGG; WHO grade II) differ sharply from the aggressive, rapidly fatal clinical course of primary glioblastoma (GBM; WHO grade IV). Nevertheless, until recently, the molecular foundations underlying this stark biological contrast between glioma variants remained largely unknown. The discoveries of distinctive and highly recurrent genomic and epigenomic abnormalities in LGG have both informed a more accurate classification scheme and pointed to viable avenues for therapeutic development...
January 2014: Neuro-oncology
Make the most of Read.
Download the mobile app.
Download the mobile app.
Fetching more papers... 
